Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Assets (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Assets for 12 consecutive years, with $715.7 million as the latest value for Q4 2025.

  • Quarterly Assets fell 21.2% to $715.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $715.7 million through Dec 2025, down 21.2% year-over-year, with the annual reading at $715.7 million for FY2025, 21.2% down from the prior year.
  • Assets hit $715.7 million in Q4 2025 for Viking Therapeutics, down from $739.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $967.5 million in Q1 2024 to a low of $150.9 million in Q1 2023.
  • Historically, Assets has averaged $492.4 million across 5 years, with a median of $375.6 million in 2023.
  • Biggest five-year swings in Assets: dropped 25.75% in 2022 and later surged 541.19% in 2024.
  • Year by year, Assets stood at $210.7 million in 2021, then dropped by 20.0% to $168.5 million in 2022, then soared by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then fell by 21.2% to $715.7 million in 2025.
  • Business Quant data shows Assets for VKTX at $715.7 million in Q4 2025, $739.4 million in Q3 2025, and $827.9 million in Q2 2025.